Maggie L. Shaw

The UPMC Health Plan Neighborhood Center, which first opened its doors in December 2022, offers a wide array of services to support plan members and others living in the community.

Approximately 70 to 300 million individuals worldwide are living with myasthenia gravis, an antibody-mediated autoimmune disorder that adversely affects neuromuscular junction function.

We are in the midst of a transformative time in oncology that could also be a little scary if you are not prepared, said Nicolas Ferreyros, managing director of policy, advocacy, and communications, Community Oncology Alliance.

In this interview from our Institute for Value-Based Medicine® event, held in partnership with the Zangmeister Cancer Center of Columbus, Ohio, on September 14, Kristine Slam, MD, FACP, Central Ohio Surgical Associates, discusses the benefits of value-based care in the breast cancer space.

Patient acceptable symptom state (PASS) may be a reliable indicator of long-term outcomes among patients who have myasthenia gravis (MG).

Specialty pharmacy is a big area of growth, with opportunity for patients, and specialty pharmacists can help payers and insurers ensure that patients get the full value of oncology medications, noted Andre Harvin, PharmD, MS, MBA, chief pharmacy officer, Oncology Services, Cone Health Cancer Centers.

Care quality is high in both the United States and Canada, but there are commonalities in regard to drug access and cost issues, particularly with advanced medications, noted G. B. John Mancini, MD, University of British Columbia.

The investigation evaluated if symptom signatures of myasthenia gravis exacerbations could be evaluated using real-world data gathered via a smartphone-based research platform.

Investigators wanted to understand potential clinical relationships between daily activity measurement and patient-centered heart failure–related outcomes using smartwatch data.

Curing cancer is something we all want to do, but logistical issues remain around translating that into practice, explained Sigrun Hallmeyer, MD, medical oncologist with Advocate Health.

With this study, investigators hoped to describe personality traits among individuals who have the autoimmune, neuromuscular disease.

Investigators conducted this subanalysis among patients aged 20 to 27 years, using data from the National Growth and Health Study to determine potential racial differences in left ventricular mass among female patients with obesity.

At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.

Three sessions of a semi-structured focus group were conducted to gain patient feedback on personalized screening for colorectal cancer (CRC).

Investigators also did not find a threshold below which this association was lost.

Data from the 1999-2018 National Health and Nutrition Examination Survey were used to analyze the prevalence of social determinants of health (SDOH) among patients with self-reported heart failure (HF).

Kevin Davies, PhD, executive editor, The CRISPR Journal and GEN Biotechnology, and author of Editing Humanity: The CRISPR Revolution and the New Era of Genome Editing, discusses the difficulties inherent in making CRISPR gene editing technology an equitable treatment.

This study compared autoantigen detection of acetylcholine receptor and muscle-specific kinase, among 3 assays used in suspected cases of myasthenia gravis.

Olalekan Ajayi, PharmD, MBA, 2023-2024 president of the Association of Community Cancer Centers, discusses what practices should do to succeed under the Enhancing Oncology Model (EOM).

Jeff Patton, MD, CEO of OneOncology, joins Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for episode 3 of "Oncology Onward: Conversations With Innovators and Changemakers in Cancer Care."

Data on 10 social determinants of health (SDOH) were analyzed to determine their distribution among low-income patients hospitalized for heart failure (HF) at a safety-net hospital.

Study authors investigated the effect of physical activity as a modifiable risk factor among individuals living with high-risk hypertension in this subanalysis of data from the Systolic Blood Pressure Intervention Trial (SPRINT).

Stephen Nicholls, PhD, MBBS, Monash University and Victorian Heart Hospital, explains how he works closely with patients and study sites in SURPASS-CVOT to avoid weight loss drug discontinuation and weight regain.

Study authors used data from the Taiwan National Healthcare Insurance Research database and Death Registry for their population-based retrospective cohort study.

Sheila Garland, PhD, MSc, Memorial University in Newfoundland, Canada talks about the cognitive effects cancer can have on patients, beyond treatment side effects, and the direct impacts these can make on patients’ lives and care.

Outcomes for these patients following bystander CPR were compared with those among White patients.

Post heart failure (HF)–related hospital discharge care was investigated among patients through evaluation of usage rates of the Heart Failure Health Storylines mobile health application.

Investigators conducted a case study of a patient who presented with COVID-19–induced seronegative myasthenia gravis, seeking more information on neurological manifestations of the respiratory disease.

Debra Patt, MD, PhD, MBA, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for episode 2 of our newest podcast, "Oncology Onward: Conversations With Innovators and Changemakers in Cancer Care."

G.B. John Mancini, MD, University of British Columbia, goes into detail about the recruitment process of the VICTORION-2-PREVENT trial, which focuses on inclisiran to reduce cardiovascular risk.